Comparative Pharmacology
Head-to-head clinical analysis: UROVIST CYSTO versus VASCORAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UROVIST CYSTO versus VASCORAY.
UROVIST CYSTO vs VASCORAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Urovist Cysto is a radiocontrast agent containing diatrizoate meglumine and diatrizoate sodium. It provides radiographic visualization of the urinary tract by attenuating X-rays due to its iodine content. It is not systemically absorbed when used intravesically; local contrast enhancement occurs through physical properties.
VASCORAY is a fixed combination of iodixanol and calcium sodium edetate. Iodixanol is a nonionic, dimeric, isotonic iodinated contrast medium that increases radiographic contrast by attenuating X-rays. Calcium sodium edetate chelates calcium, potentially reducing contrast-induced nephropathy risk.
Instillation of 50 mL of a 0.3% solution intravesically, retained for 10 minutes, for cystography.
0.5-1.0 mL/kg intravenously as a single dose, not to exceed 5 mL/kg total.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life of 8-12 hours in patients with normal renal function; prolonged in renal impairment.
Primarily renal excretion as unchanged drug (approximately 85-90% within 24 hours); minor biliary/fecal elimination (<5%).
Primarily renal (90% unchanged), with 10% biliary/fecal.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent